JP Morgan maintains Insulet at Neutral, raises price target to $170 from $152

JP Morgan kept Insulet at Neutral but raised its price target to $170 from $152, suggesting an 8.9% upside from the Nov 5 close. Recent analyst targets range from $167 to $200.

Original reporting
Published Nov 5, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Insulet at Neutral, raises price target to $170 from $152 — source image
Decision brief

The 30-second read

$PODDBullishLow
01

Why it matters

The upgrade signals confidence in Insulet's growth prospects, potentially prompting short-term buying.

02

Market read

Analyst target raise is a modest catalyst for Insulet, offering limited but actionable insight for traders.

03

What to watch

Insulet's recent product pipeline and reimbursement trends could temper upside.

Relevance 6/10Novelty 5/10Timing: pre-market tomorrow

Background

JP Morgan's analyst note updates price target based on its internal valuation model.

Company-level read

Ticker impact

$PODDBullishMedium confidence
Context

JP Morgan raised its price target on Insulet to $170 from $152, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst target upgrades often lead to short-term buying, especially when the new target implies ~9% upside from current price.

Market effects

May lift sentiment in the medical device sector.

Limited to US equities, no broader regional effect.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Insulet Corp

    Medical device maker specializing in insulin pumps.

  • JP Morgan

    Investment bank providing equity research coverage.

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.